Hodgkin's lymphoma:2023 update on treatment  

作　　者：Sicong Zhang Xianming Liu Lanfang Li Lihua Qiu Zhengzi Qian Shiyong Zhou Xianhuo Wang Huilai Zhang 

机构地区：[1]Department of Lymphoma,Tianjin Medical University Cancer Institute&Hospital,National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine,National Clinical Research Center for Cancer,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,The Sino-US Center for Lymphoma and Leukemia Research,Tianjin 300060,China

出　　处：《Cancer Biology & Medicine》2024年第4期269-273,共5页癌症生物学与医学（英文版）

摘　　要：Hodgkin's lymphoma(HL)is a common,malignant hematological tumor of the lymph nodes and lymphatic system,accounting for 10%of all lymphomas.HL comprises 2 main subtypes:classical HL(cHL)and nodular lymphocyte predominant HL.

关 键 词：LYMPHOMA TREATMENT predominant 

分 类 号：R733.1[医药卫生—肿瘤]